Grifols, S.A.
GRFS
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalentā¦ read more
Healthcare
Drug ManufacturersāGeneral
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$10.72
Price-0.19%
-$0.02
1Y
Price
Market Cap
$9.069b
Mid
Price/Earnings 3y Avg5y Avg
21x
Premium
Premium
Financials Overview
Key metrics over the past few years+20.1%
EBITDA Margin+0.8%
Net Profit Margin-11.2%
Free Cash Flow MarginRevenue
$7.446b
+3.3%
1y CAGR+11.7%
3y CAGR+6.8%
5y CAGREarnings
$297.447m
+155.9%
1y CAGR+21.0%
3y CAGR+1.5%
5y CAGREPS
$0.43
+155.6%
1y CAGR+21.4%
3y CAGR+1.9%
5y CAGRBook Value
$7.598b
$19.767b
Assets$12.169b
Liabilities$8.819b
DebtDebt to Assets
44.6%
8.2x
Debt to EBITDAFree Cash Flow
$895.923m
-55.3%
1y CAGR-71.6%
3y CAGR-69.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company